Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Profile Name | ERBB2 G778_S779insLPS |
Gene Variant Detail | |
Relevant Treatment Approaches | HER inhibitor (Pan) HER2 Inhibitor |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
ERBB2 G778_S779insLPS | Advanced Solid Tumor | resistant | Osimertinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) G778_S779insLPS were resistant to Tagrisso (osimertinib) in culture (PMID: 31588020). | 31588020 | |
ERBB2 G778_S779insLPS | Advanced Solid Tumor | resistant | HER2 Inhibitor | Sapitinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) G778_S779insLPS were resistant to Sapitinib (AZD8931) in culture (PMID: 31588020). | 31588020 |
ERBB2 G778_S779insLPS | Advanced Solid Tumor | sensitive | HER2 Inhibitor | TH-4000 | Preclinical - Cell culture | Actionable | In a preclinical study, Tarloxotinib (TH-4000) inhibited survival of transformed cells expressing ERBB2 (HER2) G778_S779insLPS in culture (PMID: 31588020). | 31588020 |
ERBB2 G778_S779insLPS | Advanced Solid Tumor | sensitive | HER inhibitor (Pan) | Dacomitinib | Preclinical - Cell culture | Actionable | In a preclinical study, Vizimpro (dacomitinib) inhibited survival of transformed cells expressing ERBB2 (HER2) G778_S779insLPS in culture (PMID: 31588020). | 31588020 |
ERBB2 G778_S779insLPS | Advanced Solid Tumor | resistant | HER2 Inhibitor | Lapatinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) G778_S779insLPS were resistant to Tykerb (lapatinib) in culture (PMID: 31588020). | 31588020 |
ERBB2 G778_S779insLPS | Advanced Solid Tumor | sensitive | HER2 Inhibitor | Ibrutinib | Preclinical - Cell culture | Actionable | In a preclinical study, Imbruvica (ibrutinib) inhibited survival of transformed cells expressing ERBB2 (HER2) G778_S779insLPS in culture (PMID: 31588020). | 31588020 |
ERBB2 G778_S779insLPS | Advanced Solid Tumor | sensitive | HER2 Inhibitor | Pyrotinib | Preclinical - Cell culture | Actionable | In a preclinical study, Pyrotinib inhibited survival of transformed cells expressing ERBB2 (HER2) G778_S779insLPS in culture (PMID: 31588020). | 31588020 |
ERBB2 G778_S779insLPS | Advanced Solid Tumor | sensitive | HER inhibitor (Pan) | Poziotinib | Preclinical - Cell culture | Actionable | In a preclinical study, Poziotinib (HM781-36B) inhibited survival of transformed cells expressing ERBB2 (HER2) G778_S779insLPS in culture (PMID: 31588020). | 31588020 |
ERBB2 G778_S779insLPS | Advanced Solid Tumor | resistant | Nazartinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) G778_S779insLPS were resistant to Nazartinib (EGF816) in culture (PMID: 31588020). | 31588020 | |
ERBB2 G778_S779insLPS | Advanced Solid Tumor | sensitive | HER inhibitor (Pan) | Afatinib | Preclinical - Cell culture | Actionable | In a preclinical study, Gilotrif (afatinib) inhibited survival of transformed cells expressing ERBB2 (HER2) G778_S779insLPS in culture (PMID: 31588020). | 31588020 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|